Escalier Biosciences is developing both topical and oral RORγt inverse agonists for the treatment of a broad spectrum of psoriasis patients – from the underserved mild-to-moderate patients that would benefit from a safe and effective topical RORγt therapeutic to the more moderate-to-severe patients that would benefit from a safe and effective oral RORγt drug in lieu of injectable biologic therapies targeting IL-17 and IL-23.

Biotechnology

Education

Escalier Biosciences

Raju Mohan

Edward Van Wezel

Chris Krueger

John Nuss

The board of directors at Escalier Biosciences has a history of experience in the medical and technological industries, as well as a wealth of knowledge in the field of gastroenterology. Many of the members have also been professors at renowned universities, such as the University of California, San Diego.

Board of Directors

CEO and Executive Team

Leadership Team

Board of Directors

About

Team members

Other teams at Escalier Biosciences

CEO and Executive Team

Leadership Team